Expanding Psychedelic Medicine – Rick Doblin, Ph.D.


MAPS is a 501(c)(3) non-profit organization developing medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. We are currently seeking funding to support our mission to make psychedelic therapy a legal treatment around the world. * Gift the gift of healing: https://maps.org/give * In MAPS’ completed Phase 2 trials with 107 participants, 56% no longer qualified for PTSD after treatment with MDMA-assisted psychotherapy, measured two months following treatment. At the 12-month follow-up, 68% no longer had PTSD. Based on these results, the FDA granted Breakthrough Therapy Designation to MDMA-assisted psychotherapy for PTSD in August 2017. By granting Breakthrough Therapy Designation, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. MAPS began Phase 3 clinical trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) in July 2019, and we are continuing to accept applications for study participants in our U.S. Food and Drug Administration (FDA)-regulated trials. We are working with the European Medicines Agency (EMA) on our proposed protocol for Phase 3 trials in Europe, and earlier this year, the Israeli Ministry of Health announced the approval of compassionate use for MDMA-assisted psychotherapy for PTSD, which will allow 50 patients to receive the therapy within a treatment protocol. * Learn more: https://maps.org * For a limited time, all gifts to MAPS will be doubled up to $100,000 by John A. Griffin! By making a tax-deductible donation to MAPS, you can help create new medicines for posttraumatic stress disorder (PTSD), anxiety, addiction, and other conditions. Together, we can make psychedelics into legal medicines. * Help us reach our fundraising goal: https://maps.org/give * Thank you for your support!